HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer.

AbstractPURPOSE:
This study investigated the preoperative serum levels of CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer.
SUBJECTS:
This study evaluated 341 patients who had undergone a complete resection for stage I NSCLC between 2002 and 2008.
RESULTS:
The patients included 193 males and 148 females. The mean age of the patients was 69.2 years (range: 19-88). The histological types included 264 adenocarcinomas, 56 squamous cell carcinomas, 11 large cell carcinomas, and 10 other types of carcinoma. A pneumonectomy was performed in 2 patients, a bilobectomy in 7, a lobectomy in 255, a segmentectomy in 46, and partial resection of the lung in 31 patients. The positive rates for CYFRA 21-1 in the adenocarcinoma and squamous cell carcinoma patients were 33.3% and 76.8%, respectively. The positive rates for CEA in adenocarcinoma and squamous cell carcinoma patients were 23.8% and 26.8%, respectively. The 5-year survival rate after surgery in the normal CYFRA 21-1 group and the high CYFRA 21-1 groups were 92.8% and 75.4%, respectively, in the patients with stage I NSCLC. There was a significant difference between the 2 groups (p<0.0001). The 5-year survival rate according to the serum level of CEA in the patients with stage I NSCLC were 88.3% for the normal group and 76.3% for the high group. In a multivariate analysis using the variables found to be significant prognostic factors in univariate analysis, a high CYFRA 21-1 level was found to be a significant independent prognostic factor (95% confidence interval 1.213-5.442, p=0.014).
CONCLUSION:
A high preoperative CYFRA 21-1 level was a significant independent prognostic factor in patients with stage I NSCLC. The patients with a high CYFRA 21-1 level should carefully followed-up to rule out occult metastasis. Further clinical studies will be necessary to evaluate the efficacy of adjuvant therapy for the patients selected according to this criterion.
AuthorsTakeshi Hanagiri, Masakazu Sugaya, Masaru Takenaka, Sohich Oka, Tetsuro Baba, Yoshiki Shigematsu, Yoshika Nagata, Hidehiko Shimokawa, Hidetaka Uramoto, Mitsuhiro Takenoyama, Kosei Yasumoto, Fumihiro Tanaka
JournalLung cancer (Amsterdam, Netherlands) (Lung Cancer) Vol. 74 Issue 1 Pg. 112-7 (Oct 2011) ISSN: 1872-8332 [Electronic] Ireland
PMID21397974 (Publication Type: Journal Article)
CopyrightCopyright © 2011 Elsevier Ireland Ltd. All rights reserved.
Chemical References
  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • Keratin-19
  • Receptors, Cell Surface
  • antigen CYFRA21.1
  • carcinoembryonic antigen binding protein, human
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, Neoplasm (genetics, metabolism)
  • Biomarkers, Tumor (metabolism)
  • Carcinoma, Non-Small-Cell Lung (diagnosis, mortality, pathology, physiopathology)
  • Disease Progression
  • Female
  • Humans
  • Keratin-19 (genetics, metabolism)
  • Lung Neoplasms (diagnosis, mortality, pathology, physiopathology)
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Preoperative Care
  • Prognosis
  • Receptors, Cell Surface (genetics, metabolism)
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: